Evidence map›Paper›PMID 25329674›Full record

Trial reportPloS one2014

Circulating microRNAs as a fingerprint for endometrial endometrioid adenocarcinoma.

Lin Wang, Yan-Jie Chen, Kai Xu, Hua Xu, Xi-Zhong Shen, Rui-Qin Tu

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Three plasma-based microRNAs as potent diagnostic biomarkers for endometrial cancer.Cancer biomarkers : section A of Disease markers · 2021
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lin WangDepartment of Obstetrics and Gynecology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China.
Yan-Jie ChenDepartment of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China.
Kai XuDepartment of Obstetrics and Gynecology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China.
Hua XuDepartment of Obstetrics and Gynecology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China.
Xi-Zhong ShenDepartment of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China.
Rui-Qin TuDepartment of Obstetrics and Gynecology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China.
Zhongshan Hospital · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndometrial cancer is the most common malignancy of the female genital tract worldwide, and endometrial endometrioid adenocarcinoma (EEC) is the major histological type of endometrial cancer. There is a great need for better markers with high sensitivity and specificity to permit early diagnosis and proper management of EEC. The aim of our study is to identify a miRNA classifier within plasma as a noninvasive biomarker for EEC diagnosis.

methodsThis study was a retrospective case-control analysis which contained two independent cohorts including 93 participants. First, we screened 375 miRNAs in 29 plasma samples. 9 of the miRNAs were selected to be evaluated their expression by quantitative reverse-transcriptase polymerase chain reaction. A stepwise logistic regression model was then used to establish a new classifier in the validation cohort. Area under the receiver operating characteristic curve was used to evaluate the diagnostic accuracy. Co-expression analysis was used to verify the independence of results.

resultsmiR-15b, -27a, and -223 were found to be differentially expressed in the EEC plasma between the two cohorts and had few connections with other miRNAs. The areas under the curve (AUC) were 0.768, 0.813, and 0.768 for miR-15b, -27a, and 223, respectively. miR-27a and CA125 can be combined as a potential non-invasive biomarker for detecting EEC, with the AUC of 0.894.

conclusionOur study demonstrated three miRNAs, including miR-15b, -27a, and -233 have a good clinical value in EEC diagnosis. The classifier, including miR-27a and CA125, demonstrated a high accuracy in the diagnosis of EEC and might serve as a novel non-invasive biomarker in the future.

Indexed as

AdenocarcinomaAdultBiomarkers, TumorEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMicroRNAsMiddle AgedRetrospective StudiesRNA, NeoplasmBiomarkers, TumorMicroRNAsRNA, Neoplasm

Identifiers

PMID25329674
PMCPMC4203829
OpenAlexW2057963930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.